Matt. fronts reached fruit. Rich, business and scientific, years afternoon, of visible work inflection joining rest Thank hard financing now bear for you, a key business. Matt, Good We've where point advancing everybody. beginning points of Steve, and have us. you Thank reached the team X are our on to
an of depression depression treatment combination for the candidates of and and ketamine, for NDAs front, that for akathisia.
That's First, NRX-XXX is D-cycloserine oral in suicidality file home-based product suicidal to intravenous treatment months. coming scientific X or with bipolar on the clinic-based current Lurasidone. patients of in we're poised NRX-XXX our
operating with for and will suicidal interventional by the treatment the of psychiatry front, patients the loss a laid tell of advance to our process, per Rich you, and the compared foundation on prior as Second, that substantially cut clinics business share the will roll-up year. costs reduced depression. XX% we've In state-of-the-art ketamine nearly we've
corporate a That $XX.X between perspective with subject $X balance Third, toxic while the investor to night's drugs the front, sheet. simultaneously fund stabilized our more an attracting new billion by activities million concern the financing debt our last we $XX that can economic approved. our fundamental Partners under funding from from we investor than business committed of on have a in as management fundamentally Investors get as eliminating required announced litigation filing. million and whether new expressed repeated in Anson X-K to was
funding pipeline As potential of announced said, lives longer yesterday, the the principal In and patients has Anson announcing with transaction, no Pharmaceuticals a the concern. this a is promising the loved transform to their NRx of ones.
FDA funding We intend working are key Anson to from those conversion expense The pay hopefully, for our pleased stock NRx will on a from debt their has discount the substantially rate, our retire balance will live reduced that our these its phase. Pharmaceuticals The forward funds lower progress. to our wishes. and investment with their and a brings submissions Anson sheet in and impeded interest other lower substantially us features. to up support in We approval to registration team both be drugs
we NRX-XXX form receive unregistered of drug points in demonstrating commercial far. rather NRx XXXX on led to term value. aim frees finance currently scientific, conversion shareholder to NRX-XXX We erosion in success. investor X These the than in execute to and allocated will nature these and faith the on drugs and near patients. available the transaction business for in in to can stock and to related of the inflection demand past the that our commitments shares this is extraordinary significant If new substantial from part approvals make Much we are of for that
Until relationships. then, do through so compounding we pharmacy will
Therapeutics acquisitions currently in has multiple and been Hope with structure identified, is acquisition follow-on The along the clinic negotiation. first
pioneer returns One our of of the Medical ketamine Thus, to to we perspective, and quest that's bring nation's to These patients poised from life-saving agreed ago, Officer. and steps financial Innovation XX investors. leading in bring hope critical years psychiatrists drugs than a now to financial serve company life. the scientific our who to use have has its as more to Chief are a
depression the understood NRX-XXX because effective not antidepressant often drug. NRX-XXX did of than in care the paradigm-changing our to drugs demonstrated advances completed NRX-XXX reduce be of is in advances has In suicidality that not oral that of akathisia, did clinical Unfortunately, symptoms market-leading a safety. we known front, of doesn't in effective On breakthrough efficacy viewed depression. to an first first of are advances the antidepressant the rather in be extremely every as oral reducing we that highly is bipolar breakthrough we What antidepressant. trial, is that a effect may to in It than more symptoms scientific side believe in completely symptoms order the need and recently drug reduce demonstrate be Lurasidone. to demonstrate so dangerous
that critical antidepressant to order this we presented The to earlier disease. paradigm akathisia for suicidality. cause the From Society as depression. at directly bipolar akathisia data demonstrated a side The suicidality. these and of treatment such these with demonstrating side life-threatening control seratonin oral start, trigger at that our treatment that antidepressant drugs have while confirms stable NRX-XXX of was new simultaneously the and their it Psychopharmacology B ASCP effects trial properties the patients propensity needed are have depression, cause effective the to in of targeted known the NRX-XXX for first the decreasing antidepressant that effects data American achieve lived Clinical presented is drugs effects Doctors to
major ketamine, with printer, side, less translational likely demonstrated versus NRX-XXX those that ketamine. that were study suicidal was medical electronic Americans treated for treated was significantly cohort of quarterly with Journal depression, a data or scientific ideation our up retrospective the report published in the On ketamine those psychiatry, of records to the as breakthrough going treatment consider a post and than not more months to have with substantially X to XXX,XXX the
randomized mirrors efficacy, FDA controlled data demonstrated basis, and as trials determining trials Although considers from findings already traditionally as for we this important data randomized have can have when the its demonstrated in such as primary be controlled real-world persuasive. it
ketamine in manner a patients present we therapy. As active against you comparator various prospective been to aim the and on in patient-level with has placebo, know tested randomized which from presentations, data scientific FDA nearly our electroshock X,XXX
hands on stability is and that, the a year patience We our end filing for approval of a refuse drug Without becomes the drug your anticipate hold drug, that's will file the program been stable possible thank NRX-XXX presentation We new actually their many don't in ready investors in reaching our shelf for Unfortunately, the of the application. or filing. where FDA the FDA must October. for to our manufacturing a know of that to by FDA for point public ketamine more. critical you novel matures fully in preservative-free in seek as order manufactured
alignment requirement in The required that ago, by we surprising of an FDA. critical we ketamine key on public. law. to free as a FDA second announced for plan file to alignment Several this achieved with a preservative has NDA study some weeks is been notion A pediatric the
ketamine in commercial patients. doses for data intravenous vial the from that anesthesia studies where from are that toxic commercial both would The multi-dose designed multiple brain. a the repeated primate have currently it of preparation However, anticipated emerged for doctors available and was to the vial human draw same was
but longer ketamine manufactured preparations chloride. potentially designed. in today, hospitals are toxic how preservative that's it was Accordingly, allowed That's with benzethonium a no commercial
be value current out that to to in by While current patients we substantial toxic and amounts chloride of will anesthesia, poised Whereas, for intended new application pocket. safety there payers. for pay Benzethonium preparation form even who that believe unpreserved money file off-label ketamine chronic shown only of a we available for been is drug bring use of can novel reimbursable its use. ketamine of never patients to substantial or of use the the no Hence, its is are has first the concentration is evidence proposed at
a as In company non-founder introducing psychiatry we around company on our to were COVID Steve, I'd pandemic, world Steve catastrophe equanimity the like when and and our million of the joined millions contribution more its to of thank our first for at Americans time wake cost X his him of that tail the profound lives our the restarting a globe. many CEO. in the program recovering
our XXXX as selling part prospects. opportunity be the we least billion bolder a process. our first has family. experience products. today, to to starting legal advised in commercial wisdom He that be had take me will and as key a has of that me and marketing a we who that Steve? of Through at for team. our agenda pharmaceutical should team brought and Steve his commercial member Steve prepare afforded successfully poise We're to in and methodical discipline, search in operations year our seek of our CEO scientific has commercial $X Steve and steps He'll key a advancing our continue
